Cupping and Serkangabin Versus Conventional Migraine Treatment

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Migraine is the most common recurrent headache. Current therapy of migraine headache consists of multiple drug groups for control of attack and prophylaxis against recurrent attacks. Emerging alternative medicine worldwide led investigators to evaluate the efficacy of cupping therapy plus SERKANGABIN syrup in treatment of migraine headache. Severity, duration and frequency of attacks of migraine headache evaluated in two groups during six months from presentation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Birjand University of Medical Sciences

Criteria

Inclusion Criteria:

• migraine headache with or without aura

Exclusion Criteria:

• uncontrolled hypertension

• ischemic heart disease

• cardiac arrhythmia or symptomatic Wolff-Parkinson-White syndrome

• previous stroke or transient ischemic attack

• severe liver or renal impairment

• any other severe or disabling medical condition

• history of alcohol or analgesic or psychotropic drug abuse

• contraindication to or known hypersensitivity to study drugs

• current use or use in the previous 2 weeks of MAO-inhibitors

• a pain disorder other than migraine as the primary presenting problem

• current psychological treatment, psychiatric disorder needing immediate or priority treatment

• current or planned breast feeding or pregnancy or unwillingness to use an established contraceptive method

• non compliance of patients

• not presenting at times determined for treatment and evaluation